Skip to main content
IL DONG PHARMACEUTICAL CO., LTD. logo

IL DONG PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 249420 ISIN · KR7249420001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-05-12 Earnings Release
Country KR South Korea
Listing KO 249420

About IL DONG PHARMACEUTICAL CO., LTD.

https://mobile.ildong.com/eng/main/main…

IL DONG PHARMACEUTICAL CO., LTD. is a pharmaceutical company engaged in the research, development, manufacturing, and commercialization of a broad range of healthcare products. The company's portfolio encompasses ethical drugs, over-the-counter (OTC) medications, active pharmaceutical ingredients (APIs), and health functional foods. Key therapeutic areas of focus include metabolic disorders, gastrointestinal diseases, degenerative diseases, oncology, and cardiovascular conditions. Its robust research and development pipeline features promising drug candidates such as an oral GLP-1 receptor agonist for diabetes and obesity, a P-CAB class treatment for peptic ulcers, and a first-in-class CXCR7 agonist for fibrotic diseases. Utilizing its GMP-certified facilities, the company also offers contract manufacturing (CMO) services, with specialized capabilities in antibiotics and oncology drugs, while actively pursuing global expansion through strategic partnerships and licensing.

Recent filings

Filing Released Lang Actions
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) from Ildong Pharmaceutical. It provides a summary table of key financial metrics (revenue, operating profit, net income) for the first quarter of 2025 compared to previous periods. It is a short, high-level announcement of financial results rather than a full quarterly report or a report publication announcement. Therefore, it fits the definition of an Earnings Release (ER). Q1 2025
2025-05-12 Korean
결산실적공시예고(안내공시)
Report Publication Announcement Classification · 100% confidence The document is a short announcement (579 characters) from Ildong Pharmaceutical notifying the public of the upcoming date for their quarterly financial results disclosure (2025-05-12). It explicitly states that the actual financial data will be published on that future date. Following the 'Menu vs Meal' rule, this is an announcement regarding the publication of a report, not the report itself, making it a Report Publication Announcement (RPA).
2025-05-07 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results from a General Meeting of Shareholders (AGM). It details the approval of financial statements, board appointments, and other resolutions passed during the meeting held on 2025-03-26. This aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2025-03-26 Korean
[기재정정]정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official filing titled '정기주주총회결과' (Results of the Annual General Meeting) for Ildong Pharmaceutical. It details the outcomes of the meeting, including the approval of financial statements, election of directors and auditors, and other resolutions passed by shareholders. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements.
2025-03-26 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment of an outside director (사외이사). It details the specific changes in board composition, including the name of the appointee, their background, and the effective date. This falls under the category of board or management changes.
2025-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, financial highlights (assets, liabilities, equity, profit/loss), and auditor information for the fiscal year ending 2024. While it contains financial data, it is a summary disclosure of the audit results rather than the full Annual Report (10-K) or a standalone audit report document. According to the classification rules, this fits the 'Audit Report / Information' (AR) category as it specifically reports on the audit opinion and financial results verified by the external auditor. FY 2024
2025-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.